विज्ञप्तियां उर्दू विज्ञप्तियां फोटो निमंत्रण लेख प्रत्यायन फीडबैक विज्ञप्तियां मंगाएं Search उन्नत खोज
RSS RSS
Quick Search
home Home
Releases Urdu Releases Photos Invitations Features Accreditation Feedback Subscribe Releases Advance Search
home  Printer friendly Page home  Email this page
English Release 2-September 2014
Date Month Year
  • Vice President's Secretariat
  • Vice President Inaugurates 89th Foundation Course at Lal Bahadur Shastri National Academy of Administration in Mussoorie
  • Prime Minister's Office
  • Text of Prime Minister Shri Narendra Modi’s remarks at the Indian Community Reception in Tokyo
  • Text of Prime Minister Shri Narendra Modi’s remarks after inaugurating the TCS Japan Technology and Culture Academy
  • Text of Prime Minister Shri Narendra Modi’s keynote address at welcome reception hosted by Japan-India Association and Japan-India Parliamentary Friendship League
  • PM inaugurates Vivekananda Cultural Centre at Indian Embassy in Tokyo
  • PM’s remarks at the Indian Community Reception in Tokyo
  • PM's keynote address at welcome reception hosted by Japan-India Association and Japan-India Parliamentary Friendship League
  • Text of Prime Minister Shri Narendra Modi’s keynote address at event organized by Nikkei Inc. and Japan External Trade Organization (JETRO)
  • PM's keynote address at event organized by Nikkei Inc. and Japan External Trade Organization (JETRO)
  • Text of Prime Minister Shri Narendra Modi’s special lecture at the University of the Sacred Heart, Tokyo
  • PM’s remarks after inaugurating the TCS Japan Technology and Culture Academy
  • PM's special lecture at the University of the Sacred Heart, Tokyo
  • Min of Agriculture
  • Government puts Agriculture Sector on Fast Track
  • Min of Defence
  • Fast Patrol Vessel ICGS Abhiraj Commissioned at Tuticorin
  • Min of Environment and Forests
  • Initiatives of the Ministry of Environment, Forests & Climate Change
  • Ministry of Finance
  • A High Level Committee Constituted for Considering the Proposals for Assessment of Income arising or accruing before 1st April, 2012 on Account of Retrospective Amendments to the Provisions Related to Indirect Transfer
  • Min of Health and Family Welfare
  • Revised strategy for Kala Azar eradication launched
  • Min of Home Affairs
  • MHA Asks Manipur Govt to Take Preventive Steps in view of UNC Blockade
  • Union Home Minister asks Kerala CM to take Strict action against Political Killings
  • Min of Information & Broadcasting
  • I&B Ministry initiatives to enhance Outreach and information dissemination through multiple platforms
  • Min of Petroleum & Natural Gas
  • Petroleum Minister emphasizes on adopting energy efficient techniques for better development of the nation
  • Global crude oil price of Indian Basket was US$ 101.29 per bbl on 01.09.2014
  • Min of Power
  • Landmark Initiatives for Energy Efficiency Launched
  • Min of Rural Development
  • Sweeping changes made in MGNREGA by Nitin Gadkari
  • Min of Science & Technology
  • Atomic Energy Regulatory Board (AERB) Releases the Annual Report for the Year 2013-14
  • MoU Signed between National Cancer Institute, AIIMS, Jhajjar Campus and DBT, GOI
  • Dr Jitendra Singh Announces DBT Collaboration in Establishing A “National Cancer Institute” at Jhajjar, Haryana.
  • Min of Tribal Affairs
  • “Single Window System” for Obtaining Market Information on Minor Forest Produces Through Toll Free Number 1800 180 1551

Previous Date

 
Ministry of Health and Family Welfare11-March, 2011 15:34 IST
Banned Medicines
The Central Government has prohibited six drugs on the recommendations of the Expert Committee constituted by DTAB in view of the safety issues involved in the use of these drugs by a Gazette Notification dated 10.02.2011 with immediate effect. The names of these drugs along with the brief reasons for their ban are furnished below:

1. Nimesulide formulations in children below 12 years of age - Nimesulide containing products are not permitted in many countries in children under 12 years of age. The drug has been considered to be hepatotoxic and children are considered more susceptible to hepatotoxicity.
2. Cisapride and its formulations for human use - Use of this drug is reported to be associated with increased risk of serious cardiac arrhythmia.
3. Phenylpropanolamine and its formulations for human use - Use of this drug is associated with risk of hypertensive episodes like cardiac congestive failures and hemorrhagic strokes.
4. Human Placental Extract and its formulations for human use - There is no clear evidence of efficacy of this drug in most of the conditions and there are safety concerns like transmission of blood borne infections, immunoreactions and unwanted exposure to hormones associated with its use.
5. Sibutramine and its formulations for human use - Use of this drug is associated with increased risk of cardiovascular events such as heart attack and stroke.
6. R-Sibutramine and its formulations for human use - Use of this drug is associated with increased risk of cardiovascular events such as heart attack and stroke.
Apart from the aforementioned six drugs banned recently, the following drugs have been banned during the last three years:

1. Rosiglitazone, on 12th November, 2010 - Use of this drug is associated with increased risk of cardiovascular events such as congestive heart failure and myocardial infarction.
2. Rimonabant, on 11th December, 2009 - Use of this drug is associated with increased risk of psychiatric side effects.
3. Diclofenac and its formulations for animal use, on 4th July, 2008 - Extensive use of this drug in animals was leading to harmful effects on vultures. The vulture population was depleting as it was observed that vultures fed on carcass of animals treated with diclofenac were dying.

The decision to ban or withdraw a drug by the regulatory authorities is normally based on the risk assessment process, which is influenced by a number of factors such as disease pattern in a country, indications and dosages of the drug permitted, varying reactions of certain ethnic groups in a given population, availability of safer substitutes and overall safety profile of the drug. These conditions are different for different countries. It is for this reason that a drug banned / restricted in one country may continue to be marketed in other countries. There is a well laid out mechanism in India to review the status of the drug formulations as and when any serious adverse event is reported in the International journals, WHO Newsletters or when a drug formulation is reported to have been banned / withdrawn in some countries. The use of the drug, so reported, is assessed in consultation with the expert committees set up for the purpose, based on available technical information, benefit-risk ratio, local needs and availability of safer alternatives etc. The Central Government prohibit manufacture and sale of drugs in the country under Section 26A of the Drugs and Cosmetics Act, 1940.

This information was given by Minister of Health & Family Welfare Sh. Ghulam Nabi Azad in reply to a question in the Lok Sabha today.

*****


SBS/RS
(Release ID :70841)

Web Ratana This site is winner of Platinum Icon for 'Outstanding Web Content' Web Ratna Award'09 presented in April 2010
Site is designed and hosted by National Informatics Centre (NIC),Information is provided and updated by Press Information Bureau
"A" - Wing, Shastri Bhawan, Dr. Rajendra Prasad Road, New Delhi - 110 001 Phone 23389338
Go Top Top

उपयोग संबंधी शर्तें स्वोत्वाधिकार नीति गोपनीयता संबंधी नीति हाइपरलिंकिंग नीति Terms of Use Copyright Policy Privacy Policy Hyperlinking Policy